An Open Label, Non-interventional Study Of The Safety Of Temsirolimus Injection (Torisel) In The Treatment Of Advanced Renal Cell Carcinoma In Filipino Adult Patients: A Post Marketing Surveillance Study
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 30 Apr 2013
Price : $35 *
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Pfizer
- 30 Apr 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 27 Mar 2013 Planned End Date changed from 1 Feb 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 08 Feb 2013 New trial record